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107Creation of an iliac arteriovenous shunt lowers
blood pressure in chronic obstructive pulmonary
disease patients with hypertension
John Faul, MD,a Danny Schoors, MD, PhD,b Soﬁe Brouwers, MD,b Benjamin Scott, MD, FSCAI,c
Andreas Jerrentrup, MD,d Joseph Galvin, MD,e Sandra Luitjens, BSc,f and Eamon Dolan, MD,g Dublin,
Ireland; Brussels and Antwerp, Belgium; Marburg, Germany; and San Clemente, Calif
Objective: Vasodilators are used with caution in patients with chronic obstructive pulmonary disease (COPD). We have
developed a device for percutaneous arteriovenous shunt creation in the iliac region to increase cardiac output and oxygen
delivery for patients with COPD. Although this device does not cause signiﬁcant blood pressure changes in normotensive
patients with COPD, we hypothesized that arteriovenous shunt creation might cause vasodilator effects in hypertensive
patients because of a reduction in vascular resistance.
Methods: Twenty-four patients with COPD and hypertension enrolled in an open label study of arteriovenous shunt
creation for COPD. We performed cardiac catheterization at baseline and again 3 to 6 months after the procedure. As
a safety measure we also recorded ofﬁce blood pressure at baseline and again after 3, 6, 9, and 12 months.
Results: The procedure increased oxygen delivery (1.1-1.4 L.minL1) and cardiac output (6-8.2 L.minL1) (P < .001) and
lowered both the systemic vascular resistance (P < .001) and the pulmonary vascular resistance (P < .01). After
12 months, however, the average systolic blood pressure was reduced from 145 to 132 mm Hg (P < .0001), and the
average diastolic blood pressure was reduced from 86 to 67 mm Hg (P < .0001).
Conclusions: Percutaneous iliac arteriovenous ﬁstula creation for COPD causes a signiﬁcant and persistent lowering of
blood pressure in patients with co-existing hypertension. (J Vasc Surg 2014;59:1078-83.)Vasodilator therapy can worsen patients with chronic
obstructive pulmonary disease (COPD).1-3 The use of
nitric oxide, for example, is contraindicated in COPD.3
Vasodilators (sildenaﬁl, for example) that affect the avail-
ability of nitric oxide are also not recommended for
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8suffer the effects of reduced systemic oxygen transport,
we have developed a percutaneous procedure that creates
a side to side iliac arteriovenous shunt with the aim of
increasing cardiac output and, hence, oxygen delivery for
patients with severe COPD.5 While the procedure has no
direct effect on airﬂow limitation or hypoxemia, some
COPD patients have experienced improved exercise
capacity5 and New York Heart Association functional
class.6 To date a signiﬁcant vasodilator effect has not
been described after this procedure.
When upper extremity end to side arteriovenous
ﬁstulae are created for dialysis patients, the procedure
causes a vasodilator effect through reductions in vascular
resistance.7 Indeed, systolic and diastolic blood pressures
are reported to be lower even before dialysis is
commenced.7 Since dialysis shunts have been shown to
lower blood pressure through a reduction in vascular resis-
tance, we hypothesized that creation of an arteriovenous
shunt for COPD might cause signiﬁcant vasodilator effects
in patients with coexistent hypertension.METHODS
This report includes all 24 patients with COPD and
who had an ofﬁce-based systolic blood pressure of
130 mm Hg or more at baseline, in spite of antihyperten-
sive therapy, and who underwent percutaneous arteriove-
nous shunt creation using the Rox Anastomotic Coupler
device (Anastomotic Coupler II; Rox Medical, San Clem-
ente, Calif) with subsequent follow-up to 1 year. Full
details of these multicenter studies of the effect of
JOURNAL OF VASCULAR SURGERY
Volume 59, Number 4 Faul et al 1079arteriovenous shunt on oxygen delivery in COPD are
found at ClinicalTrials.gov, numbers NCT00832611 and
NCT00992680. Study protocols were in accordance with
the Declaration of Helsinki and were approved by the local
Research Ethics Review Committee at each of the partici-
pating centers. All patients provided written informed
consent prior to all procedures. The study procedures
were overseen by a Data Safety and Monitoring Com-
mittee, which oversaw the conduct of the study and the
safety of the study subjects.
Each patient in this report had systolic blood pressure
recordings greater than 130 mm Hg at baseline in spite of
antihypertensive therapy and was not known to have
a secondary cause of hypertension. All patients were 50 to
80 years old, and had Global Initiative for Obstructive
Lung Disease stage II or greater COPD, were without an
exacerbation of COPD, and were on stable medication for
a minimum of 4 weeks prior to enrollment. The exclusion
criteria included a mean pulmonary arterial pressure greater
than 35 mm Hg (measured by right heart catheterization),
obesity (body mass index greater than 31 kg.m2 male or
32 kg.m2 female), liver cirrhosis, recent stroke or heart
failure (within 6 months), unstable coronary artery disease,
peripheral vascular disease, and cancer that might adversely
affect patient safety. To create an iliac arteriovenous shunt,
we deployed an investigational device through a novel
delivery system (Fig 1). The device, crossing needle, guide-
wire, and delivery system are undergoing human clinical
trials and have not yet obtained U.S. Food and Drug
Administration approval. The shunt ismaintained by a single
self-expanding nitinol anastomotic coupler (Rox Medical)
that was deployed in the iliac region. Vascular access was ob-
tained using standard interventional techniques. After arte-
rial puncture, a coiled guidewire was placed via an introducer
into the femoral artery and introduced cephalad into the
iliac artery using ﬂuoroscopic guidance (Fig 1, a). Next,
a straight guidewire was placed into the femoral vein and
introduced cephalad into the iliac vein using ﬂuoroscopic
guidance. An 11F introducer was placed over the venous
guidewire, allowing introduction of a 7F delivery catheter
delivery system. Through the 7F delivery catheter system,
a 22-gauge crossing needle was tracked up the iliac vein,
to a point where the iliac artery and vein cross over one
another (Fig 1, b). The crossing needle was then pushed
through the wall of the iliac vein into the iliac artery (using
the coiled guidewire in the lumen of the iliac artery as an
anatomical target for the crossing needle). A guidewire
was then advanced through the crossing needle from the
femoral vein to iliac vein and across the puncture into the
iliac artery. The placement of this wire was conﬁrmed by
ﬂuoroscopy. The crossing needle was removed from the
femoral vein and the coiled guidewire was removed from
the iliac artery. Next a self-expanding device was introduced
via the 7F delivery system through the femoral vein intro-
ducer and along the guidewire that followed a path from
femoral vein to iliac vein to iliac artery. The delivery catheter
was tracked up through the femoral vein and across the
puncture site and into the iliac artery. A self-expandingnitinol anastomotic coupler (Rox Medical) was then
deployed so that the expanded arms of the coupler attach
to the inner walls of the iliac artery ﬁrst, followed by a further
deployment of the remaining set of expanded arms for their
attachment to the inner walls of the iliac vein, and a set of
retention arms to maintain the coupler in the proper posi-
tion (Fig 1, c). After removal of the delivery system, a 4-
mm balloon catheter was introduced along the guidewire
and inserted into the center of the (ﬂuoroscopically visible)
anastomotic coupler. The balloon was inﬂated to further
expand the coupler to a 4-mm diameter (Fig 1, d and e).
The balloonwas then deﬂated and removedwith the delivery
system. To assess whether the procedure was successful,
an iliac arteriogram was completed at the end of the proce-
dure to conﬁrm the patency of the shunt. Manual compres-
sion was applied to achieve hemostasis at the femoral and
arterial puncture sites. Patients were prescribed aspirin and
compression stockings after the procedure.
Baseline measurements consisted of vital signs, physical
examination, and cardiac catheterization. We did follow-up
assessments at 3, 6, 9, and 12 months, which consisted of
ofﬁce blood pressure measurement, physical examination,
and surveillance for adverse events. We recorded ofﬁce
blood pressures in accordance with standard Joint National
Committee VII guidelines. Patients also underwent repeat
cardiac catheterization 3 to 6 months after implantation of
the device (creation of an arteriovenous shunt). Although
ambulatory blood pressuremeasurement (ABPM) is consid-
ered more robust than ofﬁce blood pressure measures, the
use of ABPM monitors here was considered too onerous
for patientswith severeCOPDwhowere alreadyundergoing
numerous study visits and procedures for this study of
oxygen delivery in COPD. Cardiac output was measured
in all but ﬁve subjects using a thermodilution catheter tech-
nique. In ﬁve subjects, the baseline and follow-up cardiac
output were measured using the Fick technique.
Statistical analysis. We monitored changes in ofﬁce-
based blood pressure over 12 months of follow-up and
compared it with baseline blood pressure by repeated
measures analysis of variance with pair-wise comparison of
signiﬁcant values. To assess the hemodynamic effect of
shunt creation, we compared hemodynamic measures
between baseline and repeat cardiac catheterization
(between 3 and 6 months after the creation of a shunt)
using paired t-tests. A P value of less than .05 was regarded
as statistically signiﬁcant. Multiple linear regression analysis
was performed to determine whether an association exists
between changes in hemodynamic measures and changes
in ofﬁce based blood pressure and age, sex, baseline heart
rate, and baseline severity of COPD. Analyses were per-
formed with Microsoft Excel (Microsoft Corp, Redmond,
Wash) and Graphpad Prism (GraphPad Prism Corp, San
Diego, Calif).
RESULTS
Twenty-four (13 male) COPD patients with a baseline
systolic blood pressure greater than 130 mm Hg and
a mean postbronchodilator forced expiratory volume in 1
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Fig 1. Deployment of the anastomotic clip involves passing a coiled guidewire along the iliac artery to outline the
course of the right iliac artery during ﬂuoroscopy (a). Next a 22-gauge curved needle is introduced into the iliac vein
and introduced (through the walls of the iliac vein and iliac artery, using the coiled guidewire as a target) into the lumen
of the iliac artery. A guidewire is passed through the lumen of this curved needle to conﬁrm access from the iliac vein
into the iliac artery during ﬂuoroscopy (b). Using the guidewire that leads from iliac vein to iliac artery as a guide, a 7F
delivery catheter is introduced to deploy a nitinol device between the artery and vein, allowing the creation of a 4-mm
arteriovenous ﬁstula (c-e). The procedure results in deployment of a self-expanding nitinol device that creates a central
lumen of 4-mm diameter allowing a shunt of blood from iliac artery to iliac vein.
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an arteriovenous shunt using a percutaneously deployed
nitinol anastomotic coupler device (Rox Medical) in the
iliac region. Their demographic details are contained in
Table I. Two-thirds of patients (n ¼ 16) had a systolic
blood pressure greater than 140 mm Hg at baseline, while
21% had a systolic blood pressure greater than 160 mm
Hg. There was no institution, sex, or race/ethnic based
difference in outcome. Patients took, on average, two
antihypertensive medications, with 29% receiving anangiotensin-converting enzyme inhibitor, 17% an angio-
tensin II receptor blocker, 17% beta-blockers, 25%
calcium-channel blockers, and 8% direct vasodilators.
Almost one-half (46%) of the hypertensive patients also
took diuretics (Table I).
Cardiac catheterization revealed increases in cardiac
output (from 6 [standard deviation (SD), 2] L.min1 at
baseline to 8.4 [SD, 3] L.min1; P < .001) and oxygen
delivery (from 1091 [SD, 432] mL.min1 to 1441 [SD,
518] mL.min1; P < .001), accompanied by reductions
Table II. Hemodynamic values at baseline and on repeat
cardiac catheterization postinsertion of an arteriovenous
shunt anastomotic coupler device (Rox Medical, San
Clemente, Calif) (n ¼ 23)
Baseline Repeat P value
Heart rate, bpm 91 (16) 92 (16) .85
Mean arterial pressure, mm Hg 106 (12) 97 (12) .001
Right atrial pressure, mm Hg 8 (4) 9.5 (4) .17
Cardiac output, L.min1 6 (2) 8.4 (3) <.001
Oxygen delivery, mL.min1 1091 (432) 1441 (518) <.001
Systemic vascular resistance,
dynes
1457 (483) 930 (335) <.001
Mean pulmonary arterial
pressure, mm Hg
25 (5) 29 (6) <.01
Mixed venous oxygen
saturation, %
73 (6) 79 (5) <.001
Pulmonary capillary wedge
pressure, mm Hg
12.2 (5) 15.5 (7) .01
Pulmonary vascular resistance,
dynes
190 (117) 140 (77) <.01
SD, Standard deviation.
Repeat cardiac catheterization was performed between 3 and 6 months after
creation of an arteriovenous shunt.
Data are presented as mean (SD).
Table I. Baseline demographics of the 24 patients with
chronic obstructive pulmonary disease (COPD) and high
blood pressure who underwent creation of an
arteriovenous shunt
No. of patients 24
Age, years 65 (6)
Male sex 54%
Body mass index, kg.m2 25 (5)
Cigarette consumption, pack years 47 (25)
Systolic blood pressure, mm Hg 145 (12)
Diastolic blood pressure, mm Hg 86 (13)
Mean arterial blood pressure, mm Hg 105 (12)
Serum creatinine, mg/dL 0.84 (.26)
Diuretic 46%
ACE inhibitor 29%
Angiotensin receptor blocker 17%
Beta-blocker 17%
Vasodilator (nitrate) 8%
Calcium channel blocker 25%
Postbronchodilator FVC, % predicted 68 (22)
Postbronchodilator FEV1, % predicted 30 (11)
PaO2 mm Hg on room air 63 (9)
PaCO2 mm Hg on room air 42 (6)
ACE, Angiotensin-converting enzyme; FEV, forced expiratory volume;
FVC, forced vital capacity; PaCO2, partial pressure of carbon dioxide; PaO2,
partial pressure of oxygen; SD, standard deviation.
Data are presented as mean (SD).
Fig 2. Systolic blood pressure recordings (mm Hg on Y axis)
at baseline 0 and 3, 6, 9, and 12 months after creation of an
iliac arteriovenous shunt (AVS) using an anastomotic coupler
device (Rox Medical, San Clemente, Calif) (P < .0001, by
analysis of variance). Postanalysis testing revealed signiﬁcant
differences between baseline and 6 months (**P < .01), base-
line and 9 months (*P < .05), and baseline and 12 months
(**P < .01).
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mm Hg; P < .001), systemic vascular resistance (1457
[SD, 483] to 930 [SD, 335] dynes; P < .001), and pulmo-
nary vascular resistance (190 [SD, 117] to 140 [SD, 77]
dynes; P < .01). Although there was no signiﬁcant change
in right atrial pressure or heart rate, there were small but
signiﬁcant increases in pulmonary arterial pressure (25
[SD, 5] mm Hg at baseline to 29 [SD, 6] mm Hg at
follow-up; P < .01), and pulmonary capillary wedge pres-
sure (12.2 [SD, 5] mm Hg at baseline to 15.5 [SD, 7] mm
Hg at follow-up; P ¼ .01; Table II). Multivariable regres-
sion revealed an association between changes in cardiac
output and changes in pulmonary vascular resistance
(P < .05) and between changes in cardiac output and
changes in systemic vascular resistance (P < .05). Changes
in pulmonary capillary wedge pressure were associated
with changes in systemic vascular resistance (P < .05)
but were not associated with changes in pulmonary vas-
cular resistance.
The average blood pressure measurements were
145/86, 139/76, 130/71, 132/74, and 132/67 mm
Hg at baseline, 3, 6, 9, and 12 months, respectively
(Figs 2 and 3). By the end of the study period
(12 months), the creation of the shunt had signiﬁcantly
reduced both systolic and diastolic blood pressures; the
systolic blood pressure was reduced from 145 (SD, 12)
to 132 (SD, 18) mm Hg and the diastolic blood pres-
sure was reduced from 86 (SD, 13) to 67 (SD, 13)
mm Hg (P < .0001). Multiple comparison testing
revealed signiﬁcant differences in systolic blood pressure
between baseline and 6 months, baseline and 9 months,
and baseline and 12 months. Multiple comparisontesting revealed signiﬁcant differences in diastolic blood
pressure between baseline and 3 months, baseline and
6 months, baseline and 9 months, and baseline and
12 months and a signiﬁcant difference was also seen
between 3 and 12 months. Multivariable analysis showed
a signiﬁcant association between baseline diastolic blood
pressure and changes in diastolic pressure at 12 months
(P < .02) but failed to show a clear association between
Fig 3. Diastolic blood pressure recordings (mm Hg on Y axis) at
baseline 0 and at 3, 6, 9, and 12 months after creation of an iliac
arteriovenous shunt (AVS) using an anastomotic coupler device
(Rox Medical, San Clemente, Calif) (P < .0001, by analysis of
variance). Postanalysis testing revealed differences between
baseline and 3 months (**P < .01), baseline and 6 months
(**P < .01), baseline and 9 months (**P < .01), baseline and
12 months (***P < .001).
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sex, baseline heart rate, baseline severity of COPD
(partial pressure of oxygen in arterial plasma and forced
expiratory volume in 1 second). At baseline, patients
were taking an average of two antihypertensive medica-
tions, which did not change during follow-up.
The median procedure time (from skin to skin) was
53 minutes (range, 20 minutes to 2 hours and 15 minutes).
Among the 24 patients who underwent arteriovenous
shunt creation, the procedure was completed without
complication in 20 patients. Within 7 days of the proce-
dure, two patients developed pseudoaneurysm at the
femoral access site, which was successfully treated with
manual compression, and did not have any further compli-
cation; one patient developed mild chest pressure and chest
pain, which resolved; and one patient developed a clot
around the shunt which resolved after anti-coagulant
therapy. Late adverse events included four patients who
developed deep venous thrombosis (resolved with
3 months of anticoagulation) and another patient in
whom the shunt was closed (at 11 months) because of
a perceived lack of clinical improvement. Four patients
developed a venous stenosis of the iliac vein cephalad to
the device. Two of these cases were initially treated with
dilatation; however, the stenosis recurred and was subse-
quently treated with stent placement. The remaining two
subjects with venous stenosis were all successfully treated
with stent placement without recurrence. In one case, the
stent was undersized, resulting in dislodgement and migra-
tion into the right ventricle. The stent was retrieved and
repositioned in the left iliac vein with no sequelae, andthe venous stenosis was successfully treated with an appro-
priately sized self-expanding stent. Our patients with
a long-term stent placement for the venous stenosis report
good long-term efﬁcacy without any adverse effect. There
was no death during the 12-month follow-up period.
DISCUSSION
Percutaneous iliac arteriovenous ﬁstula creation causes
a signiﬁcant and sustained vasodilator effect in hypertensive
COPD patients. One year after device implantation the
systolic blood pressure is reduced by an average of
13 mmHg and the average drop in diastolic blood pressure
is 19 mm Hg. The reduction in diastolic pressure is signif-
icantly associated with higher baseline diastolic blood pres-
sure recordings, suggesting that the vasodilator effect is
greater in patients with more severe hypertension. Almost
all these hypertensive patients have lower blood pressure
after the procedure, and the proportion of patients with
a systolic blood pressure greater than 140 mm Hg is
reduced from 67% at baseline to 33% after 12 months.
Thus, when planning iliac arteriovenous ﬁstula creation in
COPD patients with hypertension, one should consider
the procedure can have a signiﬁcant vasodilator effectdan
effect that might not be universally well tolerated by
patients with severe COPD. In our experience, normoten-
sive subjects do not develop a signiﬁcant lowering of blood
pressure after this new procedure. In one single center
study using similar techniques for iliac arteriovenous ﬁstula
creation, a shunt signiﬁcantly increased cardiac output and
oxygen delivery, but no comment was made about blood
pressure lowering.6
Percutaneous creation of an iliofemoral arteriovenous
shunt appears to cause a sustained drop in systemic arterial
blood pressure in hypertensive COPD patients. Our
demonstration of signiﬁcant hemodynamic changes
(measured by cardiac catheterization), combined with
progressive reductions in ofﬁce based blood pressure
recordings after percutaneous iliac arteriovenous shunt
creation suggest a signiﬁcant blood pressure lowering.
This new technique employs iliofemoral vascular access
with a catheter guidance system and (through a series of
crossing needles and dilators) creation of a 4-mm shunt
between the iliac artery and iliac vein. The shunt remains
patent (96% patency rate at 1 year) with the deployment
of a self-expanding nitinol vascular anastomotic coupler.
In spite of the signiﬁcant vasodilator effect, the presence
of this device is remarkably well tolerated, even in these
elderly patients with advanced lung disease. It is somewhat
reassuring that heart rates remained unchanged at all time
points after shunt creation, and although there was no
signiﬁcant adverse cardiac effect in this cohort of patients,
the procedure has the potential to cause adverse events in
patients with severe COPD. Arteriovenous shunt creation
is a common procedure in renal patients and has a predict-
able long-term safety record.8 Cardiac patients who
develop moderate femoral arteriovenous shunts after coro-
nary angioplasty have no increase in adverse cardiac
events.9 In addition to a lowering of blood pressure, other
JOURNAL OF VASCULAR SURGERY
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limiting, and the commonest late complication with this
percutaneous procedure is venous stenosis. Our approach
is to treat venous stenosis with a self-expanding stent
because angioplasty allows recurrence. Although heart
failure occurs after large arteriovenous shunt formation
(aortocaval and large arteriovenous shunts),10,11 the risk
of heart failure is not increased in dialysis patients with
moderate or small shunts. Indeed, in dialysis patients who
have arteriovenous shunts, the cardiovascular risk is less
than in patients who receive dialysis through catheters,12
suggesting that observations about heart failure and
pulmonary hypertension in the presence of arteriovenous
shunts may relate to (1) the size of the shunt and (2)
the severity of underlying disease rather than an effect of
the procedure alone.12-14 Here we chose a moderate shunt
with a diameter of 4 mm, because smaller ﬁstulae (1-2 mm)
can close spontaneously9 and larger ﬁstulae (7-8 mm or
more) carry a greater risk of heart failure.10,11
CONCLUSIONS
We cannot exclude the possibility that the blood pres-
sure effects seen here could have been either due to
improved medication compliance during the study, or
a placebo effect, or a regression to the mean. Thus, while
we cannot yet support the use of this procedure for the
treatment of hypertension, the antihypertensive effect
observed here probably merits further examination in
a controlled study of patients with severe, treatment resis-
tant hypertension. Prospective studies of hypertensive
patients using ABPM might conﬁrm or even refute our
surprising observations and might provide further informa-
tion about nocturnal dippers and daytime spikes of blood
pressure.15 If future studies of hypertensive patients
(without COPD) conﬁrm a signiﬁcant vasodilator effect,
then this novel technique might be explored as a thera-
peutic option for patients with drug-resistant hypertension.
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